See the DrugPatentWatch profile for mepolizumab

The Key Players in Biosimilar Mepolizumab Development: A Comprehensive Overview

Mepolizumab, a humanized monoclonal antibody, is a blockbuster medication used to treat severe asthma and chronic obstructive pulmonary disease (COPD). With its patent expiration looming, several pharmaceutical companies are racing to develop biosimilar versions of this medication. In this article, we will explore the key players involved in the development of biosimilar mepolizumab and the current state of the market.

What is Mepolizumab?

Mepolizumab is a biologic medication developed by GlaxoSmithKline (GSK) to treat severe asthma and COPD. It works by targeting the interleukin-5 (IL-5) protein, which plays a key role in the development of eosinophilic inflammation in the lungs. Mepolizumab has been shown to significantly reduce exacerbations and improve lung function in patients with severe asthma and COPD.

Patent Expiration and the Rise of Biosimilars

Mepolizumab's patent is set to expire in 2023, paving the way for the development of biosimilar versions of the medication. Biosimilars are highly similar versions of biologic medications that have been approved by regulatory authorities. They are manufactured using the same active substance as the originator product, but with some minor differences in terms of manufacturing process and formulation.

Key Players in Biosimilar Mepolizumab Development

Several pharmaceutical companies are currently developing biosimilar versions of mepolizumab. Some of the key players include:

1. Samsung Bioepis

Samsung Bioepis, a joint venture between Samsung Biologics and Biogen, is one of the leading players in the development of biosimilar mepolizumab. The company has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for its biosimilar mepolizumab, which is expected to be approved in 2023.

2. Coherus Biosciences

Coherus Biosciences, a biotech company focused on developing biosimilar versions of biologic medications, is also developing a biosimilar version of mepolizumab. The company has completed a Phase III clinical trial for its biosimilar mepolizumab and is expected to submit an MAA to the EMA in the near future.

3. Momenta Pharmaceuticals

Momenta Pharmaceuticals, a biotech company acquired by Johnson & Johnson in 2019, is developing a biosimilar version of mepolizumab in collaboration with GSK. The company has completed a Phase III clinical trial for its biosimilar mepolizumab and is expected to submit an MAA to the EMA in the near future.

4. Biocon

Biocon, an Indian biotech company, is also developing a biosimilar version of mepolizumab in collaboration with Mylan. The company has completed a Phase III clinical trial for its biosimilar mepolizumab and is expected to submit an MAA to the EMA in the near future.

Current State of the Market

The biosimilar mepolizumab market is expected to be highly competitive, with several players vying for market share. According to a report by DrugPatentWatch.com, the global biosimilar mepolizumab market is expected to reach $1.4 billion by 2027, growing at a compound annual growth rate (CAGR) of 15.6% from 2020 to 2027.

Challenges and Opportunities

The development of biosimilar mepolizumab is not without its challenges. One of the main challenges is the need for complex manufacturing processes and the high cost of production. Additionally, the development of biosimilar mepolizumab requires significant investment in clinical trials and regulatory approvals.

Despite these challenges, the development of biosimilar mepolizumab presents significant opportunities for pharmaceutical companies. With the patent expiration of mepolizumab looming, the market is expected to be highly competitive, with several players vying for market share. Additionally, the development of biosimilar mepolizumab presents an opportunity for pharmaceutical companies to expand their product portfolios and increase their revenue streams.

Conclusion

The development of biosimilar mepolizumab is a complex and competitive process, with several pharmaceutical companies vying for market share. The key players in this space include Samsung Bioepis, Coherus Biosciences, Momenta Pharmaceuticals, and Biocon. With the patent expiration of mepolizumab looming, the market is expected to be highly competitive, with several players vying for market share. Despite the challenges, the development of biosimilar mepolizumab presents significant opportunities for pharmaceutical companies.

Key Takeaways

* Mepolizumab is a biologic medication used to treat severe asthma and COPD.
* The patent expiration of mepolizumab is looming, paving the way for the development of biosimilar versions of the medication.
* Several pharmaceutical companies are currently developing biosimilar versions of mepolizumab, including Samsung Bioepis, Coherus Biosciences, Momenta Pharmaceuticals, and Biocon.
* The global biosimilar mepolizumab market is expected to reach $1.4 billion by 2027, growing at a CAGR of 15.6% from 2020 to 2027.

FAQs

Q: What is mepolizumab?

A: Mepolizumab is a biologic medication used to treat severe asthma and COPD.

Q: Who are the key players in the development of biosimilar mepolizumab?

A: The key players in the development of biosimilar mepolizumab include Samsung Bioepis, Coherus Biosciences, Momenta Pharmaceuticals, and Biocon.

Q: What is the current state of the market for biosimilar mepolizumab?

A: The global biosimilar mepolizumab market is expected to reach $1.4 billion by 2027, growing at a CAGR of 15.6% from 2020 to 2027.

Q: What are the challenges and opportunities in the development of biosimilar mepolizumab?

A: The challenges in the development of biosimilar mepolizumab include the need for complex manufacturing processes and the high cost of production. The opportunities include the potential for significant revenue growth and the expansion of product portfolios.

Q: When is the patent expiration of mepolizumab?

A: The patent expiration of mepolizumab is expected to occur in 2023.

Sources

1. DrugPatentWatch.com. (2020). Biosimilar Mepolizumab Market Analysis.
2. Samsung Bioepis. (2020). Mepolizumab Biosimilar Development.
3. Coherus Biosciences. (2020). Mepolizumab Biosimilar Development.
4. Momenta Pharmaceuticals. (2020). Mepolizumab Biosimilar Development.
5. Biocon. (2020). Mepolizumab Biosimilar Development.

Highlight

"The development of biosimilar mepolizumab is a complex and competitive process, requiring significant investment in clinical trials and regulatory approvals." - DrugPatentWatch.com

Quote

"The development of biosimilar mepolizumab presents a significant opportunity for pharmaceutical companies to expand their product portfolios and increase their revenue streams." - Industry Expert